Sachiko Iseki

Sachiko Iseki

Auto-generated profile, based on publicly available information

Sachiko Iseki

Department of Molecular Craniofacial Embryology and Oral Histology, Graduate School of Medical and Dental Sciences Tokyo Medical and Dental University (TMDU) Tokyo Japan

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Inflammation and Regeneration
Verified
Journal Article
Open access
PDF file
PCPornkawee Charoenlarp
Pornkawee Charoenlarp
ARArun Kumar Rajendran
Arun Kumar Rajendran
SISachiko Iseki
Sachiko Iseki
Bone is a metabolically active organ that undergoes continuous remodeling throughout life. However, many complex skeletal defects such as large traumatic bone defects or extensive bone loss after tumor resection may cause failure of bone healing. Effective therapies for these conditions typically employ combinations of cells, scaffolds, and bioactive factors. In this review, we pay attention to one of the three factors required for regeneration of bone, bioactive factors, especially the fibroblast growth factor (FGF) family. This family is composed of 22 members and associated with various biological functions including skeletal formation. Based on the phenotypes of genetically modified mice and spatio-temporal expression levels during bone fracture healing, FGF2, FGF9, and FGF18 are regarded as possible candidates useful for bone regeneration. The role of these candidate FGFs in bone regeneration is also discussed in this review.

29 November 2017 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
ASA. Sivashanmugam
A. Sivashanmugam
PCPornkawee Charoenlarp
Pornkawee Charoenlarp
SDS. Deepthi
S. Deepthi
ARArunkumar Rajendran
Arunkumar Rajendran
SNShantikumar V. Nair
Shantikumar V. Nair
Jayakumar RangasamyJayakumar Rangasamy
Jayakumar Rangasamy

16 January 2017 in Inflammation and Regeneration
Verified
Journal Article
Open access
PDF file
CMChikako Morioka
Chikako Morioka
MKMotohiro Komaki
Motohiro Komaki
ATAtsuko Taki
Atsuko Taki
IHIzumi Honda
Izumi Honda
NYNaoki Yokoyama
Naoki Yokoyama
IMIkuo Most
Ikuo Most
Periventricular leukomalacia (PVL) is a type of multifactorial brain injury that causes cerebral palsy in premature infants. To date, effective therapies for PVL have not been available. In this study, we examined whether mesenchymal stem cells (MSCs) possess neuroprotective property in a lipopolysaccharide (LPS)-induced neonatal rat PVL-like brain injury. Human umbilical cord-derived MSCs (UCMSCs) were used in this study. Four-day-old rats were intraperitoneally injected with LPS (15 mg/kg) to cause the PVL-like brain injury and were treated immediately after the LPS-injection with UCMSCs, conditioned medium prepared from MSCs (UCMSC-CM) or interferon-gamma (IFN-γ)-pretreated MSC (IFN-γ-UCMSC-CM). To assess systemic reaction to LPS-infusion, IFN-γ in sera was measured by ELISA. The brain injury was evaluated by immunostaining of myelin basic protein (MBP) and caspase-3. RT-PCR was used to quantitate pro-inflammatory cytokine levels in the brain injury, and the expression of tumor necrosis factor-stimulated gene-6 (TSG-6) or indoleamine 2,3-dioxygenase (IDO) to evaluate anti-inflammatory or immunomodulatory molecules in UCMSCs, respectively. A cytokine and growth factor array was employed to investigate the cytokine secretion profiles of UCMSCs. Elevated serum IFN-γ was observed in LPS-infused rats. The expression of IL-6, tumor necrosis factor-alpha (TNF-α), IL-1ß, and monocyte chemoattractant protein-1 (MCP-1) were increased in the brain by LPS-infusion in comparison to saline-infused control. LPS-infusion increased caspase-3-positive cells and decreased MBP-positive area in neonatal rat brains. A cytokine and growth factor array demonstrated that UCMSCs secreted various cytokines and growth factors. UCMSCs significantly suppressed IL-1ß expression in the brains and reversed LPS-caused decrease in MBP-positive area. UCMSC-CM did not reverse MBP-positive area in the injured brain, while IFN-γ-UCMSC-CM significantly increased MBP-positive area compared to control (no treatment). IFN-γ-pretreatment increased TSG-6 and IDO expression in UCMSCs. We demonstrated that bolus intraperitoneal infusion of LPS caused PVL-like brain injury in neonatal rats and UCMSCs infusion ameliorated dysmyelination in LPS-induced neonatal rat brain injury. Conditioned medium prepared from IFN-γ-pretreated UCMSCs significantly reversed the brain damage in comparison with UCMSC-CM, suggesting that the preconditioning of UCMSCs would improve their neuroprotective effects. The mechanisms underline the therapeutic effects of MSCs on PVL need continued investigation to develop a more effective treatment.

14 April 2008 in Journal of Anatomy
Verified
Journal Article
Open access
PDF file
PVPhilaiporn Vivatbutsiri
Philaiporn Vivatbutsiri
SIShizuko Ichinose
Shizuko Ichinose
MHMarjo Hytönen
Marjo Hytönen
KSKirsi Sainio
Kirsi Sainio
KEKazuhiro Eto
Kazuhiro Eto
SISachiko Iseki
Sachiko Iseki
Loss of function of the mouse forkhead/winged helix transcription factor Foxc1 induces congenital hydrocephalus and impaired skull bone development due to failure of apical expansion of the bone. In this study we investigated meningeal development in the congenital hydrocephalus (ch) mouse with spontaneous loss of function mutant of Foxc1, around the period of initiation of skull bone apical expansion. In situ hybridization of Runx2 revealed active apical expansion of the frontal bone begins between embryonic day 13.5 and embryonic day 14.5 in the wild type, whereas expansion was inhibited in the mutant. Ultrastructural analysis revealed that three layers of the meninges begin to develop at E13.5 in the basolateral site of the head and subsequently progress to the apex in wild type. In ch homozygotes, although three layers were recognized at first at the basolateral site, cell morphology and structure of the layers became abnormal except for the pia mater, and arachnoidal and dural cells never differentiated in the apex. We identified meningeal markers for each layer and found that their expression was down‐regulated in the mutant arachnoid and dura maters. These results suggest that there is a close association between meningeal development and the apical growth of the skull bones.

27 April 2005 in Journal of Anatomy
Verified
Journal Article
Closed access
PDF file
TYToshiyuki Yoshida
Toshiyuki Yoshida
LPLeonidas A. Phylactou
Leonidas A. Phylactou
JUJames B. Uney
James B. Uney
IIIsao Ishikawa
Isao Ishikawa
KEKazuhiro Eto
Kazuhiro Eto
SISachiko Iseki
Sachiko Iseki

21 January 2013 in Congenital Anomalies
Verified
Journal Article
Open access
PDF file
TNTomoko Nagayama
Tomoko Nagayama
SOShigeru Okuhara
Shigeru Okuhara
MOMasato S. Ota
Masato S. Ota
NTNoriko Tachikawa
Noriko Tachikawa
SKShohei Kasugai
Shohei Kasugai
SISachiko Iseki
Sachiko Iseki
Fibroblast growth factor (FGF) signaling is involved in skeletal development. Among total 22 FGFs, it is suggested that FGF18 functions in promotion of osteoblast differentiation. In order to elucidate the mechanism of FGF18‐dependent acceleration of osteogenesis, we implanted rhFGF18 soaked beads over mouse fetal coronal sutures using ex‐utero surgery. The coronal suture area comprises the peripheries of the developing frontal and parietal bones, separated by the sutural mesenchyme. rhFGF18 accelerated osteogenesis by promoting connection of the frontal and parietal bone domains, resulting in elimination of the sutural mesenchyme. Expression of Fgf receptors, Fgfr1, ‐2 and ‐3 involved in skeletal development, was maintained or upregulated in the developing bone domains, consistent with enhanced osteogenesis. Bone morphogenetic protein (Bmp) 2 was specifically upregulated in the skeletogenic layer and the application of Bmp antagonist, rmNoggin, inhibited rhFGF18‐dependent upregulation of osteoblast markers. These results suggest that FGF18 accelerates osteogenesis by upregulation of Bmp2 as well as maintenance or upregulation of Fgfr1, ‐2 and ‐3 expression in osteoblasts.